Wai Chun Bio-Technology 과거 수익 실적

과거 기준 확인 0/6

Wai Chun Bio-Technology은 연평균 26.7%의 비율로 수입이 증가해 온 반면, Food 산업은 연평균 3.9%의 비율로 수입이 감소했습니다. 매출은 연평균 5.6%의 비율로 증가했습니다.

주요 정보

26.7%

수익 성장률

27.1%

EPS 성장률

Food 산업 성장	0.7%
매출 성장률	5.6%
자기자본 수익률	-73.0%
순이익	-2.6%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

Is Wai Chun Bio-Technology (HKG:660) Using Too Much Debt?

Oct 31

Is Wai Chun Bio-Technology (HKG:660) Using Too Much Debt?

Oct 14

수익 및 비용 분석

Wai Chun Bio-Technology 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:660 수익, 비용 및 수입 (HKD Millions )
날짜	수익	수익	G+A 비용
31 Dec 23	559	-14	28
30 Sep 23	666	-15	33
30 Jun 23	774	-15	39
30 Jun 22	671	-14	42
31 Dec 21	495	-17	36
30 Sep 21	552	-15	38
30 Jun 21	608	-13	40
31 Mar 21	588	-10	37
31 Dec 20	568	-8	35
30 Sep 20	562	-3	33
30 Jun 20	557	2	31
31 Mar 20	568	0	32
31 Dec 19	579	-3	34
30 Sep 19	543	-28	53
30 Jun 19	507	-52	72
31 Mar 19	494	-53	71
31 Dec 18	481	-54	70
30 Sep 18	505	-36	52
30 Jun 18	528	-18	34
31 Mar 18	520	-18	32
31 Dec 17	512	-17	30
30 Sep 17	506	-15	28
30 Jun 17	500	-13	25
31 Mar 17	482	-26	38
31 Dec 16	465	-39	51
30 Sep 16	435	-41	51
30 Jun 16	404	-44	51
31 Mar 16	391	-32	37
31 Dec 15	377	-20	24
30 Sep 15	387	-19	23
30 Jun 15	396	-18	22
31 Mar 15	395	-17	23
31 Dec 14	394	-16	24
30 Sep 14	376	-17	26
30 Jun 14	358	-19	28
31 Mar 14	366	-20	31
31 Dec 13	374	-22	34

양질의 수익: 660 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 660 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 660 은(는) 수익성이 없지만 지난 5년 동안 연간 26.7% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 660 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 660 은(는) 수익성이 없어 지난 해 수익 성장을 Food 업계( -3.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 660 현재 수익성이 없기 때문에 마이너스 자본 수익률( -72.96% )을 갖습니다.

Wai Chun Bio-Technology 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Wai Chun Bio-Technology Limited to Report Second Half, 2023 Results on Feb 29, 2024

Full year 2023 earnings released: HK$0.091 loss per share (vs HK$0.086 loss in FY 2022)

Wai Chun Bio-Technology Limited to Report First Half, 2023 Results on Sep 29, 2023

Wai Chun Bio-Technology Limited to Report Second Half, 2022 Results on Feb 28, 2023

Full year 2022 earnings released: HK$0.009 loss per share (vs HK$0.008 loss in FY 2021)

Full year 2022 earnings released: HK$0.028 loss per share (vs HK$0.008 loss in FY 2021)

Recent updates

Wai Chun Bio-Technology Limited Announces Executive Changes

New major risk - Financial data availability

Wai Chun Bio-Technology Limited Announces Appointment of Fenn David as the Company Secretary, Effective June 1 ,2024

Wai Chun Bio-Technology Limited Announces Company Secretary Changes

Wai Chun Bio-Technology Limited to Report Second Half, 2023 Results on Feb 29, 2024

Wai Chun Bio-Technology Limited Announces Change of Company Secretary and Authorised Representative

Wai Chun Bio-Technology Limited Announces Appointment of Lam Ka Chun as Chief Executive Officer

Wai Chun Bio-Technology Limited Announces Appointment of Lam Ka Chun as Chief Executive Officer

Wai Chun Bio-Technology Limited, Annual General Meeting, Nov 22, 2023

Is Wai Chun Bio-Technology (HKG:660) Using Too Much Debt?

Full year 2023 earnings released: HK$0.091 loss per share (vs HK$0.086 loss in FY 2022)

Wai Chun Bio-Technology Limited to Report First Half, 2023 Results on Sep 29, 2023

Wai Chun Bio-Technology Limited Announces Board Changes

Wai Chun Bio-Technology Limited Announces Change of Company Secretary and Authorised Representative

High number of new and inexperienced directors

Wai Chun Bio-Technology Limited to Report Second Half, 2022 Results on Feb 28, 2023

High number of new and inexperienced directors

Insider recently sold HK$112k worth of stock

Wai Chun Bio-Technology Limited Announces Executive Changes

Wai Chun Bio-Technology Limited, Annual General Meeting, Dec 29, 2022

Full year 2022 earnings released: HK$0.009 loss per share (vs HK$0.008 loss in FY 2021)

High number of new and inexperienced directors

Wai Chun Bio-Technology Limited Provides Earning Guidance for Eighteen Months Ended 30 June 2022

High number of new and inexperienced directors

Is Wai Chun Bio-Technology (HKG:660) Using Too Much Debt?

Wai Chun Bio-Technology Limited Announces Board Changes

Wai Chun Bio-Technology Limited Announces Appointment of Independent Non-Executive Director and Change in Composition of Board Committees

Full year 2022 earnings released: HK$0.028 loss per share (vs HK$0.008 loss in FY 2021)

Wai Chun Bio-Technology Limited to Report Fiscal Year 2022 Results on Oct 31, 2022

Wai Chun Bio-Technology Limited to Report First Half, 2022 Results on Sep 30, 2022

Wai Chun Bio-Technology Limited Announces Board Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Wai Chun Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Wai Chun Bio-Technology Limited to Report Second Half, 2021 Results on Feb 28, 2022

Wai Chun Bio-Technology Limited Announces Management Changes

Wai Chun Bio-Technology Limited Announces Lam Ching Kui, Executive Director, the Chief Executive Officer and Chairman Pleaded Guilty in the Eastern Magistrate's Court

Wai Chun Bio-Technology Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

CFO & Company Secretary has left the company

Executive Chairman & CEO recently bought HK$1.1m worth of stock

Wai Chun Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

Wai Chun Bio-Technology Limited announced that it expects to receive HKD 44.131223 million in funding

Wai Chun Bio-Technology Limited Appoints Chan Cheuk Ho as Independent Non-Executive Director

Wai Chun Bio-Technology Limited Appoints Wan Bo as an Independent Non-Executive Director, Member of the Nomination Committee, Member of the Audit Committee and Member of Remuneration Committee

Wai Chun Bio-Technology Limited to Report First Half, 2020 Results on Aug 28, 2020

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기